Related Experiment Video
Updated: May 10, 2026

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
Published on: January 3, 2025
A new strategy to target regulatory T cells in solid tumors
Audrey Thomas-Schoemann1, Frédéric Batteux, Jérôme Alexandre
1Université Paris Descartes ; Unité de Formation et de Recherche des Sciences Pharmaceutiques et Biologiques; Paris, France ; Université Paris Descartes; Sorbonne Paris Cité; Faculté de Médecine; Paris, France ; Unité Fonctionnelle de Pharmacocinétique et Pharmacochimie; Assistance Publique-Hôpitaux de Paris; Hôpital Cochin; Paris, France.
Abstract:
The depletion of regulatory T cells (Tregs) is a promising therapeutic strategy to enhance antitumor immune responses. Our recent findings indicate that low doses of arsenic trioxide can delay tumor growth in murine models of colon and breast cancer by depleting Tregs through oxidative and nitrosative bursts.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

